Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP51A1 | Q16850 | 4/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA5A | P35218 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.39 |
| ▸ | SMO | Q99835 | 2/20 | 0.38 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.35 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.35 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.34 |
| ▸ | SCN1A | P35498 | 1/20 | 0.34 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.34 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15590856 | 0.81 | CYP51A1 (0.49) | CYP51A1CA1CA2CA5ACA9 | |
| SCHEMBL30874461 | 0.81 | CYP51A1 (0.49) | CYP51A1CA1CA2CA5ACA9 | |
| SCHEMBL16748959 | 0.80 | CA1 (0.58) | CYP51A1CA1CA2CA5ACA9 | |
| SCHEMBL19145450 | 0.77 | CYP51A1 (0.46) | CYP51A1CA1CA2CA5ACA9 | |
| SCHEMBL20553240 | 0.77 | CA1 (0.48) | CYP51A1CA1CA2CA5ACA9 | |
| SCHEMBL13449507 | 0.77 | TP53 (0.48) | CYP51A1CA1CA2CA5ACA9 | |
| SCHEMBL16242461 | 0.77 | CA1 (0.48) | CYP51A1CA1CA2CA5ACA9 | |
| SCHEMBL15617808 | 0.77 | CYP51A1 (0.46) | CYP51A1CA1CA2CA5ACA9 | |
| SCHEMBL14190008 | 0.77 | CYP51A1 (0.46) | CYP51A1CA1CA2CA5ACA9 | |
| SCHEMBL13455265 | 0.77 | PLAU (0.47) | CYP51A1CA1CA2CA5ACA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115548397-A | Preparation method and application of cross-linked anion exchange membrane | 宿迁时代储能科技有限公司 | 2022-12-30 | — | — | CN | claimed |
| WO-2024243701-A1 | WATER-SOLUBLE N-HETEROCYCLIC CARBENE METAL NANOCLUSTERS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2024-12-05 | — | — | WO | disclosed |
| CN-117986811-A | High-alkali-resistance self-contained microporous ion membrane and preparation method and application thereof | 中国科学技术大学 | 2024-05-07 | — | — | CN | disclosed |
| CN-116041766-A | Fluorine-containing crosslinked anion exchange membrane and preparation method and application thereof | 宿迁时代储能科技有限公司 | 2023-05-02 | — | — | CN | disclosed |
| CN-115548397-A | Preparation method and application of cross-linked anion exchange membrane | 宿迁时代储能科技有限公司 | 2022-12-30 | — | — | CN | disclosed |
| US-20210207188-A1 | BETA-LACTAM COMPOUNDS AND METHODS OF USE THEREOF | THE UNIVERSITY OF HONG KONG (HK) | 2021-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210207188-A1 | BETA-LACTAM COMPOUNDS AND METHODS OF USE THEREOF | MGAM, SI, PGLS | CYP51A1 175/4885CA1 1237/4885CA2 561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.